Value proposition

Developing next generation DDR targeting therapies

Nodus oncology is developing first and best-in-class molecules inhibiting novel targets within the DNA damage response and replication stress response.
Supported by most recent scientific advances, we are developing the next wave of cancer therapeutics in the DNA damage response (DDR) area.
Founded by Cumulus Oncology and in partnership with the Lead discovery Center, Nodus Oncology is developing an innovative portfolio focused on synthetic lethality and collateral vulnerabilities in molecularly defined cancer patient populations

Oncology